Havana, October 27 (RHC)-- The production of the Cuban anti-Covid-19 Abdala vaccine reached 40 million doses, a figure described as a milestone for science in the Caribbean country, highlighted the CIGB, designer of that drug.

On  Twitter, the Center for Genetic Engineering and Biotechnology (CIGB) said that thanks to the bold decision to join efforts and resources with the Food Information and Control Agency (AICA), the immunogen was guaranteed for the health of our people and other nations that need it.

Abdala, the first vaccine in Cuba and Latin America, showed an effectiveness of 90 percent in severe patients and against the Delta variant of the SARS-CoV-2 virus and 92.28 percent against symptomatic disease with a three-dose schedule at intervals of zero, 14, and 28 days.

The doses produced were intended to immunize the population over 19 years of age, including pregnant women, nursing mothers, transplant recipients, adolescents, and young people in terminal grades of the national education system.

Due to the safety demonstrated in the mass vaccination campaign and previous studies such as Ismaelillo in children from three to 18 years old, the president of the Biotechnological and Pharmaceutical Industries Group (BioCubaFarma), Eduardo Martinez, informed that they are evaluating its application in a future clinical trial with children under two years old.